Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

54.65 -0.13 (-0.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,617,234
Open 54.73
Bid (Size) 54.10 (1)
Ask (Size) 54.40 (1)
Prev. Close 54.78
Today's Range 52.70 - 55.35
52wk Range 8.280 - 99.41
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock. 
Via The Motley Fool
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $7,500 Today
Via Benzinga

Performance

YTD
+198.96%
+198.96%
1 Month
-6.41%
-6.41%
3 Month
+3.64%
+3.64%
6 Month
-18.55%
-18.55%
1 Year
+246.32%
+246.32%

More News

Read More
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Via Benzinga
Prediction: This Biotech Stock Will Outperform Nvidia in the Second Half of the Year
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
(VKTX) - Analyzing Viking Therapeutics's Short Interest
Via Benzinga
Unpacking the Latest Options Trading Trends in Viking Therapeutics
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $800 Today
Via Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now
Via The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
Via Investor's Business Daily
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
Via Benzinga
Why Viking Therapeutics Stock Got Thrashed on Tuesday
Via The Motley Fool
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
Via Investor's Business Daily
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Via The Motley Fool
Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?
Via The Motley Fool
Big Pharma Stocks: Who’s Leading The Race And Who’s Slipping?
Via Talk Markets
Could Viking Therapeutics Become the Next Novo Nordisk?
Via The Motley Fool
3 Promising Biotech Stocks for the Long-Term: August 2024
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
Via The Motley Fool
Here's Why Eli Lilly Stock Dropped 12% Last Month
Via The Motley Fool
3 Unstoppable Stocks to Buy in August
Via The Motley Fool
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
Via The Motley Fool
What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.